Yeh, Ting-KuangTing-KuangYehJean, Shio-ShinShio-ShinJeanLee, Yu-LinYu-LinLeeLu, Min-ChiMin-ChiLuKo, Wen-ChienWen-ChienKoLin, Hsueh-JuHsueh-JuLinLiu, Po-YuPo-YuLiuPO-REN HSUEH2022-04-282022-04-282022-010924-8579https://scholars.lib.ntu.edu.tw/handle/123456789/608172Multidrug-resistant (MDR) bacterial infections in humans are increasing worldwide. The global spread of antimicrobial resistance poses a considerable threat to human health. Phage therapy is a promising approach to combat MDR bacteria. An increasing number of reports have been published on phage therapy and the successful application of antibacterials derived using this method. Additionally, the CRISPR-Cas system has been used to develop antimicrobials with bactericidal effects in vivo. The CRISPR-Cas system can be delivered into target bacteria in various ways, with phage-based vectors being reported as an effective method. In this review, we briefly summarise the results of randomised control trials on bacteriophage therapy. Moreover, we integrated mechanisms of the CRISPR-Cas system antimicrobials in a schematic diagram and consolidated the research on phage-delivered CRISPR-Cas system antimicrobials.enAntimicrobial; Bacteriophage therapy; CRISPR-Cas; Phage-based vector[SDGs]SDG3review10.1016/j.ijantimicag.2021.106475347679172-s2.0-85119524012WOS:000743513900005https://scholars.lib.ntu.edu.tw/handle/123456789/589827